These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 13484916)

  • 21. On the mechanism of action of myleran.
    WINKLER A; UJHAZY V; CERNY V
    Neoplasma; 1957; 4(4):340-4. PubMed ID: 13504380
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
    Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
    Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful pregnancy following busulfan and cyclophosphamide conditioning and allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Matias K; Matias C; Teixeira H; Freire AD; Azevedo A
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):944-5. PubMed ID: 18640580
    [No Abstract]   [Full Text] [Related]  

  • 24. Chronic myeloid leukemia.
    Singhal N; Bapsy PP; Babu KG; George J
    J Assoc Physicians India; 2004 May; 52():410-6. PubMed ID: 15656033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chronic myeloid leukosis treated with 1-4-dimethane sulfonyl oxybutane; secondary pancytopenia].
    LANGERON L; CROCCEL L; ROUTIER G; BOYAVAL M
    J Sci Med Lille; 1959 Mar; 77(3):123-7. PubMed ID: 13655267
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
    Volkova SA; Prytkova MV; Borovkov NN
    Klin Med (Mosk); 2004; 82(3):45-50. PubMed ID: 15114775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
    Takama H; Tanaka H; Nakashima D; Ueda R; Takaue Y
    Bone Marrow Transplant; 2006 Feb; 37(4):345-51. PubMed ID: 16400337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses.
    Garban F; Drillat P; Makowski C; Jacob MC; Richard MJ; Favrot M; Sotto JJ; Bensa JC; Cahn JY
    Haematologica; 2005 Aug; 90(8):1096-101. PubMed ID: 16079109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Busulfan in hematopoietic stem cell transplant setting.
    McCune JS; Holmberg LA
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):957-69. PubMed ID: 19611402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation.
    Abdul-Hai A; Weiss L; Ergas D; Resnick IB; Slavin S; Shapira MY
    Bone Marrow Transplant; 2007 Nov; 40(9):891-6. PubMed ID: 17768389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
    Fouillard L; Labopin M; Meloni G; Polge E; Gorin NC; Frassoni F
    Haematologica; 2004 Jan; 89(1):107-8. PubMed ID: 14754615
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
    Kanda Y; Sakamaki H; Sao H; Okamoto S; Kodera Y; Tanosaki R; Kasai M; Hiraoka A; Takahashi S; Miyawaki S; Kawase T; Morishima Y; Kato S;
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):881-9. PubMed ID: 16275591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current approach to diagnosis and treatment of acute leukemia in adults].
    Labar B; Nemet D; Sucić M; Batinić D; Zadro R; Mrsić S; Serventi-Seiwerth R; Sertić D; Mikulić M; Duraković N
    Acta Med Croatica; 2008 Oct; 62(4):403-8. PubMed ID: 19205417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of polycythemia vera with 1, 4-dimethylsulfonoxybutane].
    ROUQUES L
    Presse Med (1893); 1959 Feb; 67(7):260. PubMed ID: 13633863
    [No Abstract]   [Full Text] [Related]  

  • 36. Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy.
    HAUT A; ABBOTT WS; WINTROBE MM; CARTWRIGHT GE
    Blood; 1961 Jan; 17():1-19. PubMed ID: 13712355
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
    Kerbauy FR; Tirapelli B; Akabane H; Oliveira JS
    Bone Marrow Transplant; 2009 Jun; 43(11):883-5. PubMed ID: 19079309
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent.
    Bitan M; Or R; Shapira MY; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
    Haematologica; 2005 Aug; 90(8):1089-95. PubMed ID: 16079108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.
    Hempel G; Oechtering D; Lanvers-Kaminsky C; Klingebiel T; Vormoor J; Gruhn B; Boos J
    J Clin Oncol; 2007 May; 25(13):1772-8. PubMed ID: 17470868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients.
    Wingard JR
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):99-107. PubMed ID: 17336260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.